Core Viewpoint - The Boston Scientific Corporation is facing a class action lawsuit for alleged violations of the Securities Exchange Act of 1934, with claims that the company and its executives made misleading statements regarding its financial outlook and market position [1][3]. Group 1: Class Action Details - The class action lawsuit is titled Troike v. Boston Scientific Corporation, and it includes purchasers of Boston Scientific common stock from July 23, 2025, to February 3, 2026 [1]. - Investors have until May 4, 2026, to seek appointment as lead plaintiff in the lawsuit [1]. - The lawsuit alleges that Boston Scientific misrepresented its revenue outlook and downplayed risks associated with market competition and macroeconomic factors [3]. Group 2: Financial Performance - On February 4, 2026, Boston Scientific reported its fourth quarter and full year 2025 financial results, showing a GAAP net income of $672 million or $0.45 per share for Q4 2025, compared to $566 million or $0.38 per share a year ago [4]. - For the full year 2025, the company reported a GAAP net income of $2.898 billion or $1.94 per share, up from $1.853 billion or $1.25 per share the previous year [4]. - The adjusted EPS for Q4 2025 was $0.80, compared to $0.70 a year ago, and for the full year, it was $3.06, compared to $2.51 a year ago [4]. - Following the financial results announcement, Boston Scientific's stock price fell by more than 17% [4]. Group 3: Legal Representation - Robbins Geller Rudman & Dowd LLP is representing investors in the class action lawsuit and is recognized as a leading law firm in securities fraud litigation [6]. - The firm has recovered over $916 million for investors in 2025 and has a history of significant recoveries in securities class actions [6].

Core Viewpoint - A class action lawsuit has been filed against Camping World Holdings, Inc. for allegedly misleading investors regarding its business strength and inventory management capabilities during the specified class period [1][3]. Group 1: Lawsuit Details - The lawsuit is initiated by Berger Montague on behalf of investors who acquired Camping World shares from April 29, 2025, to February 24, 2026 [1][2]. - Investors have until May 11, 2026, to seek appointment as lead plaintiff representatives [2]. Group 2: Allegations Against Camping World - The complaint claims that Camping World overstated consumer retail demand and its ability to manage inventory effectively, failing to disclose necessary corrective measures that would adversely affect gross profit and margins [3]. - The company is accused of misleading investors about its operational strength, which led to significant stock price declines as the true state of operations became apparent [3]. Group 3: Stock Performance Impact - Following the company's report of declining new vehicle revenue and shrinking margins, shares fell by $4.17 (24.8%) to close at $12.65 on October 29, 2025 [4]. - After announcing substantial losses and a suspension of its quarterly dividend, shares dropped an additional $1.79 (16.5%) to close at $9.06 on February 25, 2026, resulting in considerable investor losses [4].

Core Viewpoint - New Fortress Energy, Inc. is under investigation for possible securities fraud, with a potential class action being considered for affected investors [1] Financial Performance - On May 15, 2025, New Fortress's stock price dropped by $4.27, or 63%, closing at $2.51 per share, significantly impacting investors [2] - The decline followed the release of the Company's Q1 2025 financial results, which reported revenue of $470.5 million, falling short of consensus expectations [2] Operational Challenges - A Reuters report indicated that New Fortress's financial difficulties stemmed from its inability to secure liquefied natural gas for its Latin American power-generation assets through long-term contracts [2] - The Company’s non-investment-grade credit rating forced it to purchase gas at higher prices, exacerbating its financial strain alongside disappointing revenue figures [2]

Core Viewpoint - G-III Apparel Group's shares dropped approximately 11.4% following the announcement of disappointing Q4 FY 2025 results, which included a $17.5 million bad-debt charge and a net loss of $31.9 million, leading to potential legal actions from investors [1][3]. Financial Performance - The company reported a $17.5 million bad-debt charge related to the bankruptcy of Saks, which had been hinted at throughout 2025 [2]. - For FY 2026, the Non-GAAP EPS was reported at $2.61, falling short by $0.19 to $0.29 compared to the previously raised guidance of $2.80-$2.90, attributed entirely to the Saks bankruptcy [3]. - The GAAP Net Income was reported at $67.4 million, representing a 45% shortfall against the midpoint of December's guidance [3].

Core Viewpoint - Immutep Ltd. experienced a significant stock decline of approximately 80% to 90% following the recommendation from an Independent Data Monitoring Committee to halt the Phase III TACTI-004 trial due to an interim futility analysis indicating the drug was unlikely to meet efficacy endpoints [1][2]. Group 1: Company Performance - The TACTI-004 trial was Immutep's lead clinical-stage oncology program, and prior to the halt, the company had reported "strong operational progress" and indicated that the futility analysis was "on track for the first quarter of CY2026" in a filing dated January 30, 2026 [2]. - Following the announcement on March 13, 2026, the stock fell dramatically in a single session, reflecting investor reaction to the trial's discontinuation [2]. Group 2: Legal Investigation - Levi & Korsinsky is investigating whether Immutep failed to adequately disclose material information regarding the status and interim results of the TACTI-004 futility analysis prior to the March 13 announcement [3]. - Shareholders who incurred losses on their investments in Immutep are encouraged to submit their information as part of the investigation [3].

Core Viewpoint - A class action lawsuit has been filed against Boston Scientific Corporation, alleging that executives misrepresented the growth of U.S. electrophysiology (EP) procedure volumes, leading to significant investor losses [1][2]. Group 1: Lawsuit Details - The class action seeks to recover damages for investors who purchased Boston Scientific securities between July 23, 2025, and February 3, 2026 [2]. - Boston Scientific shares experienced a significant decline of $16.12, dropping from $91.62 to $75.50, which represents a single-day decrease of 17.6% on February 4, 2026 [3]. - Investors have until May 4, 2026, to seek lead plaintiff status in the lawsuit [3]. Group 2: Allegations of Misrepresentation - The lawsuit claims that Boston Scientific's management was aware of a material slowdown in U.S. EP procedure volume growth and increasing competitive pressures but continued to project sustained market leadership and expansion [3][4]. - Management characterized the EP market as the "largest" and "fastest growing" in medtech while allegedly concealing adverse trends, including reimbursement structures that were only established in October 2024 [4]. - The complaint highlights that the pace of new site openings could not sustain the growth rates projected by management, contradicting their aggressive forward guidance [4]. Group 3: Financial Performance and Projections - The EP segment reported a 94% sales growth in Q2 2025, which was inflated due to the comparison with the initial FARAPULSE U.S. launch [6]. - Management projected long-term EP market growth at 15% and an increase in PFA penetration from 50% to 80% by 2028 [6]. - Claims were made that cath labs were performing over 30% more procedures following the FARAPULSE introduction, suggesting unlimited capacity, while Q3 2025 EP sales growth of 63% was presented as evidence of continued share gains despite a decelerating trend [6].

Core Viewpoint - Driven Brands Holdings Inc. is facing a securities fraud lawsuit due to alleged misleading financial statements that resulted in significant investor losses, with shares dropping nearly 40% following the disclosure of financial restatements [2][4]. Financial Misrepresentation - The lawsuit highlights a pattern of alleged misrepresentations starting from the Q1 2023 10-Q filing, which reported a 20% revenue growth to $562 million, but contained errors related to an unreconciled cash balance that inflated revenue and understated operating expenses [2][3]. - The amended 2023 10-K/A reported total net revenue of $2.304 billion for fiscal year 2023, which allegedly included the same unreconciled cash errors, indicating a flawed financial picture for investors [3]. Disclosure Failures - From May 9, 2023, to November 5, 2025, nine consecutive SEC filings reportedly contained material errors in revenue, cash balances, and operating expenses [4]. - On November 5, 2025, management certified that disclosure controls were effective, which was later proven false when internal controls were acknowledged as ineffective on December 27, 2025 [3][4]. - The Audit Committee concluded there were material errors across at least ten categories of financial reporting on February 23, 2026, just two days before public disclosure [4]. Stock Performance Impact - Following the announcement of the restatement on February 25, 2026, Driven Brands' stock fell from $16.61 to $9.99 per share, marking a loss of $6.62 per share, which represents a nearly 40% decline [2][4].

Core Viewpoint - The article discusses a pending securities fraud class action lawsuit against Camping World Holdings, Inc. (CWH), alleging that the company and its management concealed significant inventory deterioration, leading to substantial financial losses for investors [1][5]. Group 1: Financial Impact - CWH shares experienced a decline of 24.8% on October 29, 2025, closing at $12.65, followed by an additional drop of 16.5% on February 25, 2026, closing at $9.06, after disclosures revealed a $109.1 million net loss and the suspension of the quarterly cash dividend [2]. - The February 2026 disclosure indicated a $38.7 million decline in gross profit and a 247 basis point contraction in total gross margin, with SG&A improvement of only 190 basis points compared to prior guidance of 300 to 400 basis points [4]. Group 2: Allegations and Legal Framework - The lawsuit, filed in the United States District Court for the Northern District of Illinois, alleges violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, claiming that the company's assertions regarding its inventory management capabilities were misleading [5]. - The lawsuit contends that the company's purported ability to manage inventory using sophisticated data analytics lacked a reasonable basis, and the need for corrective inventory management objectives was not disclosed in a timely manner [5]. Group 3: Institutional Investor Considerations - Institutional investors holding CWH securities during the class period are encouraged to evaluate lead plaintiff opportunities, as the Private Securities Litigation Reform Act of 1995 provides a structured process for lead plaintiff appointment [2][6]. - The PSLRA favors appointing the movant with the largest financial interest as lead plaintiff, providing institutional holders with a procedural advantage without additional financial obligations [6]. - The court has set May 11, 2026, as the deadline for applying for lead plaintiff appointment, emphasizing the importance of fiduciaries evaluating recovery opportunities in securities class actions [6].

Core Viewpoint - A class action securities lawsuit has been filed against Oracle Corporation, alleging securities fraud that negatively impacted investors between June 12, 2025, and December 16, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit aims to recover losses for Oracle investors affected by alleged securities fraud during the specified period [2]. - The complaint claims that Oracle's AI infrastructure strategy would lead to significant increases in capital expenditures without corresponding near-term revenue growth [3]. - It is alleged that the increased spending poses serious risks to Oracle's debt, credit rating, free cash flow, and project funding capabilities [3]. Group 2: Next Steps for Investors - Investors who suffered losses in Oracle during the relevant timeframe have until April 6, 2026, to request appointment as lead plaintiff [4]. - Participation in the lawsuit does not require serving as a lead plaintiff, and there are no out-of-pocket costs for class members [4]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [5].

EOSE Investor Alert: EOS Energy Enterprises, Inc. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Allegedly Concealing Battery Line Deficiencies: Levi & Korsinsky Accessibility StatementSkip NavigationAlert: Claims Focus on Alleged Misrepresentations About Manufacturing Downtime and Production QualityNEW YORK, March 25, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP reminds purchasers of EOS Energy Enterprises, Inc. (NASDAQ: EOSE) securities of a pending securities class ...